Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk
- PMID: 35020532
- DOI: 10.1080/14712598.2022.2028772
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources